Adopting STING agonist cyclic dinucleotides as a potential adjuvant for SARS-CoV-2 vaccine

Published: July 24, 2020, 7:55 p.m.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.24.217570v1?rss=1 Authors: Wu, J.-J., Chen, Y.-X., Li, Y.-M. Abstract: A novel STING agonist CDGSF unilaterally modified with phosphorothioate and fluorine was synthesized. CDGSF displayed better STING activity over dithio CDG. Immunization of SARS-CoV-2 Spike protein with CDGSF as an adjuvant elicited an exceptional high antibody titer and a robust T cell response, which were better than the group using aluminium hydroxide as a adjuvant. These results highlighted the adjuvant potential of STING agonist in SARS-CoV-2 vaccine preparation for the first time. Copy rights belong to original authors. Visit the link for more info